{"success":true,"data":{"pressRelease":{"id":"4536","rtpr_id":"nGNX7CvfF2","ticker":"CRBP","exchange":"NASDAQ","all_tickers":["CRBP"],"title":"Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701","author":"Globe Newswire","published_at":"2026-04-22T12:00:00.603Z","article_body":"NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals\nHoldings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising\nnew therapies in oncology and obesity, today announced that updated clinical\ndata from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in\nboth head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be\npresented at the upcoming 2026 American Society of Clinical Oncology (ASCO)\nAnnual Meeting\n(https://www.globenewswire.com/Tracker?data=tOWPvxYzsjwYOS1NH6HoiNe4ax7gQD2ljSTxScaSm96swub1xzmorUZeacw7upR6-GvsEclmCSLgaqcIW2imQNGFfhsTc31Hc4499VyGlzM=),\nto be held May 29 – June 2 in Chicago, IL.\n\nThe data will include clinical response durability as well as HNSCC patient\nsubgroup analysis. Corbus previously presented dose optimization data from the\nstudy, including encouraging efficacy and safety findings, at the 2025\nEuropean Society for Medical Oncology Congress (ESMO 2025).\n\nOral Presentation\nA phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug\nconjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical\ncancer - (Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique\nBerton, MD, Institut de Cancérologie de l'Ouest; et al)\n\nPresenter: Professor Yohann Loriot, Gustave Roussy (Paris) \nSession Date and Time:  May 29, 4:57 PM CDT\nSession Title:  Gynecological Cancer\nAbstract #: 5508\n\nPoster Presentation:\nA phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug\nconjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and\nneck squamous cell carcinoma - (Charlene Mantia, MD, Glenn J Hanna, MD; Dana\nFarber, et al)\n\nPresenter: Charlene Mantia, MD, Dana Farber Cancer Institute (Boston)\nSession Date and Time:  May 30, 4:30 PM CDT\nSession Title:  Head and Neck Cancer\nAbstract #: 6062\nPoster Board: 519 \n\nThe abstracts will be available on the ASCO(®) website on May 21, 2026 at\n5:00 p.m. ET.\n\nCorbus expects to initiate a registrational study for CRB-701 in second-line\nHNSCC in mid-2026.\nCorbus also anticipates reporting data with CRB-701 in combination with\nKeytruda(®) in first-line HNSCC patients in Q4 2026 to support potential\nfurther registration-enabling trials.\n\nAbout CRB-701\nCRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting\nNectin-4, that contains a site-specific, cleavable linker and a homogenous\ndrug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically\nvalidated, tumor-associated antigen in urothelial cancer. The FDA has granted\ntwo Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701\nis licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.\n\nAbout Corbus \nCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on\npromising new therapies in oncology and obesity and is committed to helping\npeople defeat serious illness by bringing innovative scientific approaches to\nwell-understood biological pathways. Corbus’ pipeline includes CRB-701, a\nnext-generation antibody drug conjugate for the treatment of\nNectin-4-expressing tumors, and CRB-913, an orally delivered highly\nperipherally restricted CB1 inverse agonist for the treatment of obesity.\nCorbus is headquartered in Norwood, Massachusetts. For more information on\nCorbus, visit corbuspharma.com\n(https://www.globenewswire.com/Tracker?data=3BPn6f77dD3_V5uzBWmAKMsjNWqBs4suv8PbleGpaphDFomi1y2CsnLwDVxVrJOzFnPOKxVCdx1mAuhPeGZ_YdwwvJEanIMyPMB9SiSu7buGThNLpWjets4yXz1nwuEKnLfgmJ10mU2zfI81dd6LM3A1ErXP-jPeDAQ_2uParLr2oaflm4lRPSSbdrfQmpQ0Ud12qecu9zklafzgMcsiNnmrKoXq6xeT-QUrkcXsMz1TlRgBLK-kyG4DWWyoVlcB1f0MrvL530ie0-sBqsFYoTFJVRDpOEogN6wMshaGmIhvlvXFY2t7vNeNL472FK18QkVtChUot0Bm1u-0Q4VVkZ3Ea8nezU_OORMG5MqW6Z423vEW3XclcMIypy0F1qprF9XaNYAD4PINmVQ_Dz3s70vVt_6bWYsRg92J3W2Qp8kt_wt_yGg3xFkPKN7bHE3iiYx6NPvP4e-igdBIZaINmhMOnyydDV2KxggmDfjIGPM=).\nConnect with us on X\n(https://www.globenewswire.com/Tracker?data=QhE5aRaBNhDhxnlXKT1SD6Z-gC_2Vo3TZ-Ftt9ung452-3WbSq8nBLTuJVptEFUqRSk4catDOLymWNcrE-eU5uPcyJHLnHz4z1L4R0f5YKIqASS90315TydACaowGM8ZgFdaAj6V7IIjP2wUWz_yG4Yss2V1mVRKmRgOjHzmn7GWLSblNL44r9F_kAqJIxoy3yYL0lx6Z4RgUj3lw7N_6Q4RMkLRTbdO9_2jvMXrvKOqqJfuuYbVKPxpEQ6OHhPGh44mShmM1-biwgpEpCqLi9VGzum2nuP0igJOhUZThHCNZ3taYtCU6GD7tdTIFrNNR85fnjjN62wzoLeV-ACrkfujod7l8z3VAk0jMGqbfOWpulVBma2eYFbyedjmPm1s),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=HjUy0EWhGbk1cQzS7qXwBtq3r4zE0623i-_pQgkQQaHb8rPAtjiELnlucXVY7jhSFh_WJaL1tpx2zFJrtVLljwCdw25tLRZ_m1mCwJmfytjhC2gYNfyoK3lbmnKg9pHxUsgxaeYrkvzuV04h_3FXjgo6eSQZjWVQq8G5kycRyJylCfGnrBu9tx9Wuc7rfQaOdIPpyZznxX2fumNjIJcuHIJs4QOF7kC-0g1C941Q5ShX5wKnBQJTHWr3qnbH-MB4ROBMRvXQB5ygiLlBBXO6bI1G5ddOYY3bZQ7Qu36j_qVOeSXWAgC0MtbpomQXl-Lql9myBtwkYdPkxT3SDGLf0eStAfC7y54QCaxX8UEKanm236IlQ-2Ka0VWwo0oHEmqRJs3jM858waaMszoZWCZQUC68wtQIkyQxYyJqm9ZUtbkpv5KbeZoXe31wKGZL6NI7g4olml-CuvMHJLdJdbzYXBN-reVCOl7uPkYrNGQeKc=)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=L67YnVkE6VOC9wm27eKBdCoktJ1CkxzbQ3jZSXYjvdDpU1r4OwCSlKQI6onhAaurJ-X2tpXPtgNWE20pJKTjXFROfH3Cmd1ogHcfTCjAKOus9HOwdRbJJIEDf7w6Gd4iNIUpTC_0cqIIQukntRlkUqhH8ISxakai6lfEdG3WKYE-NAHQJGLeD4Lo35LQyiAGalewsIKFyDDgSa_XO6l-VLKJBEixAB-oZbrXjpQgpOaj3y7RGlJZTtQ3phjZ_TizsWeefbQlG1Cx_kFmlJG3_EPd4HpwMqlpwl2FN9PRsFvnVjfapvsz_0-qN56vSCfXywXlSR57db6x1I_-CKogzIcs_OtwwCtx0lsoaa6ncpV2_1VTXwlqTzTHO6ADfzefBKGKYRcD9dpyZTAT_ZjrBPVLdOC7AsSMdKB1pEzu7Ig-U4XeC3PsHiuvNU251UqT).\n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934 and Private Securities Litigation Reform Act,\nas amended, including those relating to the Company’s trial results, product\ndevelopment, clinical and regulatory timelines, including timing for\ncompletion of trials and presentation of data, market opportunity, competitive\nposition, possible or assumed future results of operations, business\nstrategies, potential growth opportunities and other statement that are\npredictive in nature. These forward-looking statements are based on current\nexpectations, estimates, forecasts and projections about the industry and\nmarkets in which we operate and management’s current beliefs and\nassumptions.\n\nThese statements may be identified by the use of forward-looking expressions,\nincluding, but not limited to, “expect,” “anticipate,” “intend,”\n“plan,” “believe,” “estimate,” “potential,” “predict,”\n“project,” “should,” “would” and similar expressions and the\nnegatives of those terms. These statements relate to future events or our\nfinancial performance and involve known and unknown risks, uncertainties, and\nother factors on our operations, clinical development plans and timelines,\nwhich may cause actual results, performance or achievements to be materially\ndifferent from any future results, performance or achievements expressed or\nimplied by the forward-looking statements. Such factors include those set\nforth in the Company’s filings with the Securities and Exchange Commission.\nProspective investors are cautioned not to place undue reliance on such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company undertakes no obligation to publicly update any\nforward-looking statement, whether as a result of new information, future\nevents or otherwise.\n\nINVESTOR CONTACTS:\nSean Moran\nChief Financial Officer\nCorbus Pharmaceuticals\nsmoran@corbuspharma.com\n\nDan Ferry\nManaging Director\nLifeSci Advisors, LLC\ndaniel@lifesciadvisors.com\n\nMEDIA CONTACT:\nLiz Melone\nFounder & Principal\nMelone Communications, LLC\nliz@melonecomm.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/459d6fb1-b336-4d47-8aa1-f9198bda891d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7CvfF2","title":"Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701","author":"Globe Newswire","ticker":"CRBP","created":"2026-04-22T12:00:00.603Z","tickers":["CRBP"],"exchange":"NASDAQ","article_body":"NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals\nHoldings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising\nnew therapies in oncology and obesity, today announced that updated clinical\ndata from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in\nboth head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be\npresented at the upcoming 2026 American Society of Clinical Oncology (ASCO)\nAnnual Meeting\n(https://www.globenewswire.com/Tracker?data=tOWPvxYzsjwYOS1NH6HoiNe4ax7gQD2ljSTxScaSm96swub1xzmorUZeacw7upR6-GvsEclmCSLgaqcIW2imQNGFfhsTc31Hc4499VyGlzM=),\nto be held May 29 – June 2 in Chicago, IL.\n\nThe data will include clinical response durability as well as HNSCC patient\nsubgroup analysis. Corbus previously presented dose optimization data from the\nstudy, including encouraging efficacy and safety findings, at the 2025\nEuropean Society for Medical Oncology Congress (ESMO 2025).\n\nOral Presentation\nA phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug\nconjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical\ncancer - (Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique\nBerton, MD, Institut de Cancérologie de l'Ouest; et al)\n\nPresenter: Professor Yohann Loriot, Gustave Roussy (Paris) \nSession Date and Time:  May 29, 4:57 PM CDT\nSession Title:  Gynecological Cancer\nAbstract #: 5508\n\nPoster Presentation:\nA phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug\nconjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and\nneck squamous cell carcinoma - (Charlene Mantia, MD, Glenn J Hanna, MD; Dana\nFarber, et al)\n\nPresenter: Charlene Mantia, MD, Dana Farber Cancer Institute (Boston)\nSession Date and Time:  May 30, 4:30 PM CDT\nSession Title:  Head and Neck Cancer\nAbstract #: 6062\nPoster Board: 519 \n\nThe abstracts will be available on the ASCO(®) website on May 21, 2026 at\n5:00 p.m. ET.\n\nCorbus expects to initiate a registrational study for CRB-701 in second-line\nHNSCC in mid-2026.\nCorbus also anticipates reporting data with CRB-701 in combination with\nKeytruda(®) in first-line HNSCC patients in Q4 2026 to support potential\nfurther registration-enabling trials.\n\nAbout CRB-701\nCRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting\nNectin-4, that contains a site-specific, cleavable linker and a homogenous\ndrug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically\nvalidated, tumor-associated antigen in urothelial cancer. The FDA has granted\ntwo Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701\nis licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.\n\nAbout Corbus \nCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on\npromising new therapies in oncology and obesity and is committed to helping\npeople defeat serious illness by bringing innovative scientific approaches to\nwell-understood biological pathways. Corbus’ pipeline includes CRB-701, a\nnext-generation antibody drug conjugate for the treatment of\nNectin-4-expressing tumors, and CRB-913, an orally delivered highly\nperipherally restricted CB1 inverse agonist for the treatment of obesity.\nCorbus is headquartered in Norwood, Massachusetts. For more information on\nCorbus, visit corbuspharma.com\n(https://www.globenewswire.com/Tracker?data=3BPn6f77dD3_V5uzBWmAKMsjNWqBs4suv8PbleGpaphDFomi1y2CsnLwDVxVrJOzFnPOKxVCdx1mAuhPeGZ_YdwwvJEanIMyPMB9SiSu7buGThNLpWjets4yXz1nwuEKnLfgmJ10mU2zfI81dd6LM3A1ErXP-jPeDAQ_2uParLr2oaflm4lRPSSbdrfQmpQ0Ud12qecu9zklafzgMcsiNnmrKoXq6xeT-QUrkcXsMz1TlRgBLK-kyG4DWWyoVlcB1f0MrvL530ie0-sBqsFYoTFJVRDpOEogN6wMshaGmIhvlvXFY2t7vNeNL472FK18QkVtChUot0Bm1u-0Q4VVkZ3Ea8nezU_OORMG5MqW6Z423vEW3XclcMIypy0F1qprF9XaNYAD4PINmVQ_Dz3s70vVt_6bWYsRg92J3W2Qp8kt_wt_yGg3xFkPKN7bHE3iiYx6NPvP4e-igdBIZaINmhMOnyydDV2KxggmDfjIGPM=).\nConnect with us on X\n(https://www.globenewswire.com/Tracker?data=QhE5aRaBNhDhxnlXKT1SD6Z-gC_2Vo3TZ-Ftt9ung452-3WbSq8nBLTuJVptEFUqRSk4catDOLymWNcrE-eU5uPcyJHLnHz4z1L4R0f5YKIqASS90315TydACaowGM8ZgFdaAj6V7IIjP2wUWz_yG4Yss2V1mVRKmRgOjHzmn7GWLSblNL44r9F_kAqJIxoy3yYL0lx6Z4RgUj3lw7N_6Q4RMkLRTbdO9_2jvMXrvKOqqJfuuYbVKPxpEQ6OHhPGh44mShmM1-biwgpEpCqLi9VGzum2nuP0igJOhUZThHCNZ3taYtCU6GD7tdTIFrNNR85fnjjN62wzoLeV-ACrkfujod7l8z3VAk0jMGqbfOWpulVBma2eYFbyedjmPm1s),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=HjUy0EWhGbk1cQzS7qXwBtq3r4zE0623i-_pQgkQQaHb8rPAtjiELnlucXVY7jhSFh_WJaL1tpx2zFJrtVLljwCdw25tLRZ_m1mCwJmfytjhC2gYNfyoK3lbmnKg9pHxUsgxaeYrkvzuV04h_3FXjgo6eSQZjWVQq8G5kycRyJylCfGnrBu9tx9Wuc7rfQaOdIPpyZznxX2fumNjIJcuHIJs4QOF7kC-0g1C941Q5ShX5wKnBQJTHWr3qnbH-MB4ROBMRvXQB5ygiLlBBXO6bI1G5ddOYY3bZQ7Qu36j_qVOeSXWAgC0MtbpomQXl-Lql9myBtwkYdPkxT3SDGLf0eStAfC7y54QCaxX8UEKanm236IlQ-2Ka0VWwo0oHEmqRJs3jM858waaMszoZWCZQUC68wtQIkyQxYyJqm9ZUtbkpv5KbeZoXe31wKGZL6NI7g4olml-CuvMHJLdJdbzYXBN-reVCOl7uPkYrNGQeKc=)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=L67YnVkE6VOC9wm27eKBdCoktJ1CkxzbQ3jZSXYjvdDpU1r4OwCSlKQI6onhAaurJ-X2tpXPtgNWE20pJKTjXFROfH3Cmd1ogHcfTCjAKOus9HOwdRbJJIEDf7w6Gd4iNIUpTC_0cqIIQukntRlkUqhH8ISxakai6lfEdG3WKYE-NAHQJGLeD4Lo35LQyiAGalewsIKFyDDgSa_XO6l-VLKJBEixAB-oZbrXjpQgpOaj3y7RGlJZTtQ3phjZ_TizsWeefbQlG1Cx_kFmlJG3_EPd4HpwMqlpwl2FN9PRsFvnVjfapvsz_0-qN56vSCfXywXlSR57db6x1I_-CKogzIcs_OtwwCtx0lsoaa6ncpV2_1VTXwlqTzTHO6ADfzefBKGKYRcD9dpyZTAT_ZjrBPVLdOC7AsSMdKB1pEzu7Ig-U4XeC3PsHiuvNU251UqT).\n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934 and Private Securities Litigation Reform Act,\nas amended, including those relating to the Company’s trial results, product\ndevelopment, clinical and regulatory timelines, including timing for\ncompletion of trials and presentation of data, market opportunity, competitive\nposition, possible or assumed future results of operations, business\nstrategies, potential growth opportunities and other statement that are\npredictive in nature. These forward-looking statements are based on current\nexpectations, estimates, forecasts and projections about the industry and\nmarkets in which we operate and management’s current beliefs and\nassumptions.\n\nThese statements may be identified by the use of forward-looking expressions,\nincluding, but not limited to, “expect,” “anticipate,” “intend,”\n“plan,” “believe,” “estimate,” “potential,” “predict,”\n“project,” “should,” “would” and similar expressions and the\nnegatives of those terms. These statements relate to future events or our\nfinancial performance and involve known and unknown risks, uncertainties, and\nother factors on our operations, clinical development plans and timelines,\nwhich may cause actual results, performance or achievements to be materially\ndifferent from any future results, performance or achievements expressed or\nimplied by the forward-looking statements. Such factors include those set\nforth in the Company’s filings with the Securities and Exchange Commission.\nProspective investors are cautioned not to place undue reliance on such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company undertakes no obligation to publicly update any\nforward-looking statement, whether as a result of new information, future\nevents or otherwise.\n\nINVESTOR CONTACTS:\nSean Moran\nChief Financial Officer\nCorbus Pharmaceuticals\nsmoran@corbuspharma.com\n\nDan Ferry\nManaging Director\nLifeSci Advisors, LLC\ndaniel@lifesciadvisors.com\n\nMEDIA CONTACT:\nLiz Melone\nFounder & Principal\nMelone Communications, LLC\nliz@melonecomm.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/459d6fb1-b336-4d47-8aa1-f9198bda891d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T12:00:01.154631991Z","server_sent_at_ms":1776859201154},"received_at":"2026-04-22T12:00:01.206Z","source_url":null},"analysis":{"id":"3188","press_release_id":"4536","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Corbus Pharmaceuticals announced that updated clinical data from its Phase 1/2 study of CRB-701 will be presented at the ASCO 2026 Annual Meeting, covering head and neck and cervical cancers.\n\nThe company provided developmental guidance, expecting to initiate a registrational study for CRB-701 in second-line HNSCC by mid-2026 and report combination data with Keytruda in Q4 2026.\n\nCRB-701 is a next-generation Nectin-4 ADC licensed from CSPC Megalith Biopharmaceutical and holds Fast Track designations in both oncology indications.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"ASCO presentation and mid-2026 registrational study initiation solidify CRB-701 pathway for Corbus."},"keyFigures":{"drugName":"CRB-701 (SYS6002)","phaseOfTrial":"Phase 1/2","customDimensions":{"conference_dates":"May 29 – June 2","combo_data_readout":"Q4 2026","abstract_availability":"May 21, 2026","registrational_study_start":"mid-2026"}},"quotedText":"Corbus expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026.","namedEntities":{"people":[{"name":"Sean Moran","role":"Chief Financial Officer"},{"name":"Yohann Loriot","role":"Presenter"},{"name":"Charlene Mantia","role":"Presenter"}],"products":["CRB-701","SYS6002","Keytruda","CRB-913"],"companies":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd.","relationship":"licensor"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"Melone Communications, LLC","relationship":"public relations"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The announcement confirms ASCO presentation of updated data for CRB-701 and provides specific timeline guidance for a mid-2026 registrational study initiation, which is significant for a clinical-stage biotech but not a binary regulatory event."},"tickerRelevance":{"others":[],"primary":"CRBP"},"eventTypeSecondary":["guidance_update"]},"event_type":"clinical_trial","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Corbus Pharmaceuticals announced that updated clinical data from its Phase 1/2 study of CRB-701 will be presented at the ASCO 2026 Annual Meeting, covering head and neck and cervical cancers.\n\nThe company provided developmental guidance, expecting to initiate a registrational study for CRB-701 in second-line HNSCC by mid-2026 and report combination data with Keytruda in Q4 2026.\n\nCRB-701 is a next-generation Nectin-4 ADC licensed from CSPC Megalith Biopharmaceutical and holds Fast Track designations in both oncology indications.","key_figures":{"drugName":"CRB-701 (SYS6002)","phaseOfTrial":"Phase 1/2","customDimensions":{"conference_dates":"May 29 – June 2","combo_data_readout":"Q4 2026","abstract_availability":"May 21, 2026","registrational_study_start":"mid-2026"}},"named_entities":{"people":[{"name":"Sean Moran","role":"Chief Financial Officer"},{"name":"Yohann Loriot","role":"Presenter"},{"name":"Charlene Mantia","role":"Presenter"}],"products":["CRB-701","SYS6002","Keytruda","CRB-913"],"companies":[{"name":"CSPC Megalith Biopharmaceutical Co. Ltd.","relationship":"licensor"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"},{"name":"Melone Communications, LLC","relationship":"public relations"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T14:13:52.926Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.105Z"}},"durationMs":233408,"modelName":"glm-4.7"}}